Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...
Posted by Michael Wonder on 25 Apr 2022
FDA approves first COVID-19 treatment for young children
25 April 2022 - Today, the US FDA expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include paediatric ...
Posted by Michael Wonder on 25 Apr 2022
Swissmedic grants conditional marketing authorisation for Novavax COVID-19 vaccine
13 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine authorised for use in Switzerland. ...
Posted by Michael Wonder on 21 Apr 2022
COVID-19 vaccine weekly safety report (24 April 2022)
24 April 2022 - To 17 April 2022, the TGA has received 534 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 Apr 2022
Novavax announces approval of Nuvaxovid COVID-19 vaccine for primary and booster immunisation in Japan
19 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in ...
Posted by Michael Wonder on 18 Apr 2022
Switzerland approves its first protein-based Covid vaccine
15 April 2022 - Swissmedic announced its approval on Wednesday making Nuvaxovid the first protein-based vaccine to be licensed in Switzerland. ...
Posted by Michael Wonder on 15 Apr 2022
Valneva COVID-19 vaccine approved by MHRA
14 April 2022 - The COVID-19 vaccine developed by Valneva has today been given regulatory approval by the MHRA. ...
Posted by Michael Wonder on 15 Apr 2022
Evusheld receives Health Canada approval for pre-exposure prophylaxis (prevention) of COVID-19 in immune-compromised individuals
14 April 2022 - Evusheld is the first long-acting antibody combination to receive Health Canada authorisation for the prevention of ...
Posted by Michael Wonder on 14 Apr 2022
COVID-19 vaccine weekly safety report (14 April 2022)
14 April 2022 - To 10 April 2022, the TGA has received 528 reports which have been assessed as likely to ...
Posted by Michael Wonder on 13 Apr 2022
Paxlovid ‘inaccessible’ to many patients in Canada. Here’s why that needs to change.
13 April 2022 - A pill to treat COVID-19 appears to be the country’s best hope, outside of vaccines and ...
Posted by Michael Wonder on 13 Apr 2022
Highest risk COVID-19 patients receive ‘brilliant’ new antivirals at home
9 April 2022 - Thousands of patients with COVID-19 who are most likely to be admitted to hospital are receiving ...
Posted by Michael Wonder on 11 Apr 2022
New COVID-19 oral treatment on PBS
11 April 2022 - Greg Hunt's swan song press release. ...
Posted by Michael Wonder on 09 Apr 2022
ATAGI statement on use of booster doses in adolescents aged 12-15 years
8 April 2022 - A statement from the ATAGI on booster doses in adolescents aged 12-15 years. ...
Posted by Michael Wonder on 08 Apr 2022
TGA provisionally approves Pfizer’s COVID-19 vaccine (Comirnaty), for use as a booster for individual aged 12–15 years old
8 April 2022 - The TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, Comirnaty, for use as a ...
Posted by Michael Wonder on 07 Apr 2022
TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (Xevudy) for the BA.2 omicron sublineage
7 April 2022 - The TGA has received an application from GSK for a higher (1,000 mg) dose of its ...